rolofylline has been researched along with cardiovascular agents in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bloomfield, DM; Cotter, G; Dittrich, HC; Massie, BM; Metra, M; O'Connor, CM; Weatherley, BD | 1 |
| Givertz, MM; Slawsky, MT | 1 |
| Ambrosy, AP; Butler, J; Gheorghiade, M; Greene, SJ; Vaduganathan, M | 1 |
2 review(s) available for rolofylline and cardiovascular agents
| Article | Year |
|---|---|
Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure.
Topics: Adenosine A1 Receptor Antagonists; Animals; Cardiovascular Agents; Clinical Trials as Topic; Dose-Response Relationship, Drug; Heart Failure; Humans; Renal Insufficiency, Chronic; Syndrome; Xanthines | 2009 |
The disconnect between phase II and phase III trials of drugs for heart failure.
Topics: Animals; Benzazepines; Cardiovascular Agents; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Evidence-Based Medicine; Heart Failure; Humans; Hydrazones; Natriuretic Peptide, Brain; Patient Readmission; Patient Selection; Pyridazines; Pyridines; Risk Assessment; Risk Factors; Simendan; Tetrazoles; Time Factors; Tolvaptan; Treatment Outcome; Xanthines | 2013 |
1 trial(s) available for rolofylline and cardiovascular agents
| Article | Year |
|---|---|
The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment.
Topics: Acute Disease; Adenosine A1 Receptor Antagonists; Aged; Cardiovascular Agents; Confidence Intervals; Disease Progression; Diuresis; Dyspnea; Female; Heart Failure; Humans; Male; Pilot Projects; Renal Insufficiency; Risk; Risk Factors; Xanthines | 2008 |